H2 histamine receptor blockade in the treatment of Alzheimer disease: A randomized, double-blind, placebo-controlled trial of nizatidine

Michelle C Carlson, JoAnn T. Tschanz, Maria C. Norton, Kathleen Welsh-Bohmer, Barbara K. Martin, John C.S. Breitner

Research output: Contribution to journalArticle

Abstract

Objectives: To evaluate the efficacy of nizatidine, a histamine H2-blocking drug, in delaying the progression of cognitive impairment in older adults with Alzheimer disease (AD). Design: A one-year, randomized, double-blind, placebo-controlled trial. Participants: Fifty-one older men and women aged 67 to 96 years with AD were recruited from the Cache County Study on Memory in Aging. Methods: Patients were stratified by age and by the presence of one or more ε4 alleles at the APOE locus, then randomized to receive nizatidine 75 mg (Axid AR®, Whitehall Robins) or a matching placebo tablet twice daily. Cognitive outcomes were assessed at baseline, six, and twelve months after enrollment using tests from the CERAD battery and additional measures of visuospatial memory, verbal memory, and verbal fluency. Results: Subjects showed significant declines in language, fluency, and praxis but most measures of memory had already "bottomed out." Intention-to-treat and compliance-based analyses showed no effect of nizatidine on any of the cognitive outcome measures over the one-year study interval. Conclusions: These results do not support claims for the efficacy of nizatidine in over-the-counter dosages as a means of preventing symptom progression in AD.

Original languageEnglish (US)
Pages (from-to)24-30
Number of pages7
JournalAlzheimer Disease and Associated Disorders
Volume16
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Nizatidine
Histamine H2 Receptors
Alzheimer Disease
Placebos
Therapeutics
Songbirds
Histamine
Tablets
Compliance
Language
Alleles
Outcome Assessment (Health Care)
Pharmaceutical Preparations

Keywords

  • Alzheimer disease
  • Cognitive decline
  • Dementia
  • H2RAs
  • Histamine receptor antagonists
  • Nizatidine
  • Randomized controlled trial

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

H2 histamine receptor blockade in the treatment of Alzheimer disease : A randomized, double-blind, placebo-controlled trial of nizatidine. / Carlson, Michelle C; Tschanz, JoAnn T.; Norton, Maria C.; Welsh-Bohmer, Kathleen; Martin, Barbara K.; Breitner, John C.S.

In: Alzheimer Disease and Associated Disorders, Vol. 16, No. 1, 2002, p. 24-30.

Research output: Contribution to journalArticle

@article{3d7d2d3c3ff84e949076a840ecf0fbbb,
title = "H2 histamine receptor blockade in the treatment of Alzheimer disease: A randomized, double-blind, placebo-controlled trial of nizatidine",
abstract = "Objectives: To evaluate the efficacy of nizatidine, a histamine H2-blocking drug, in delaying the progression of cognitive impairment in older adults with Alzheimer disease (AD). Design: A one-year, randomized, double-blind, placebo-controlled trial. Participants: Fifty-one older men and women aged 67 to 96 years with AD were recruited from the Cache County Study on Memory in Aging. Methods: Patients were stratified by age and by the presence of one or more ε4 alleles at the APOE locus, then randomized to receive nizatidine 75 mg (Axid AR{\circledR}, Whitehall Robins) or a matching placebo tablet twice daily. Cognitive outcomes were assessed at baseline, six, and twelve months after enrollment using tests from the CERAD battery and additional measures of visuospatial memory, verbal memory, and verbal fluency. Results: Subjects showed significant declines in language, fluency, and praxis but most measures of memory had already {"}bottomed out.{"} Intention-to-treat and compliance-based analyses showed no effect of nizatidine on any of the cognitive outcome measures over the one-year study interval. Conclusions: These results do not support claims for the efficacy of nizatidine in over-the-counter dosages as a means of preventing symptom progression in AD.",
keywords = "Alzheimer disease, Cognitive decline, Dementia, H2RAs, Histamine receptor antagonists, Nizatidine, Randomized controlled trial",
author = "Carlson, {Michelle C} and Tschanz, {JoAnn T.} and Norton, {Maria C.} and Kathleen Welsh-Bohmer and Martin, {Barbara K.} and Breitner, {John C.S.}",
year = "2002",
doi = "10.1097/00002093-200201000-00004",
language = "English (US)",
volume = "16",
pages = "24--30",
journal = "Alzheimer Disease and Associated Disorders",
issn = "0893-0341",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - H2 histamine receptor blockade in the treatment of Alzheimer disease

T2 - A randomized, double-blind, placebo-controlled trial of nizatidine

AU - Carlson, Michelle C

AU - Tschanz, JoAnn T.

AU - Norton, Maria C.

AU - Welsh-Bohmer, Kathleen

AU - Martin, Barbara K.

AU - Breitner, John C.S.

PY - 2002

Y1 - 2002

N2 - Objectives: To evaluate the efficacy of nizatidine, a histamine H2-blocking drug, in delaying the progression of cognitive impairment in older adults with Alzheimer disease (AD). Design: A one-year, randomized, double-blind, placebo-controlled trial. Participants: Fifty-one older men and women aged 67 to 96 years with AD were recruited from the Cache County Study on Memory in Aging. Methods: Patients were stratified by age and by the presence of one or more ε4 alleles at the APOE locus, then randomized to receive nizatidine 75 mg (Axid AR®, Whitehall Robins) or a matching placebo tablet twice daily. Cognitive outcomes were assessed at baseline, six, and twelve months after enrollment using tests from the CERAD battery and additional measures of visuospatial memory, verbal memory, and verbal fluency. Results: Subjects showed significant declines in language, fluency, and praxis but most measures of memory had already "bottomed out." Intention-to-treat and compliance-based analyses showed no effect of nizatidine on any of the cognitive outcome measures over the one-year study interval. Conclusions: These results do not support claims for the efficacy of nizatidine in over-the-counter dosages as a means of preventing symptom progression in AD.

AB - Objectives: To evaluate the efficacy of nizatidine, a histamine H2-blocking drug, in delaying the progression of cognitive impairment in older adults with Alzheimer disease (AD). Design: A one-year, randomized, double-blind, placebo-controlled trial. Participants: Fifty-one older men and women aged 67 to 96 years with AD were recruited from the Cache County Study on Memory in Aging. Methods: Patients were stratified by age and by the presence of one or more ε4 alleles at the APOE locus, then randomized to receive nizatidine 75 mg (Axid AR®, Whitehall Robins) or a matching placebo tablet twice daily. Cognitive outcomes were assessed at baseline, six, and twelve months after enrollment using tests from the CERAD battery and additional measures of visuospatial memory, verbal memory, and verbal fluency. Results: Subjects showed significant declines in language, fluency, and praxis but most measures of memory had already "bottomed out." Intention-to-treat and compliance-based analyses showed no effect of nizatidine on any of the cognitive outcome measures over the one-year study interval. Conclusions: These results do not support claims for the efficacy of nizatidine in over-the-counter dosages as a means of preventing symptom progression in AD.

KW - Alzheimer disease

KW - Cognitive decline

KW - Dementia

KW - H2RAs

KW - Histamine receptor antagonists

KW - Nizatidine

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=0036221888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036221888&partnerID=8YFLogxK

U2 - 10.1097/00002093-200201000-00004

DO - 10.1097/00002093-200201000-00004

M3 - Article

C2 - 11882746

AN - SCOPUS:0036221888

VL - 16

SP - 24

EP - 30

JO - Alzheimer Disease and Associated Disorders

JF - Alzheimer Disease and Associated Disorders

SN - 0893-0341

IS - 1

ER -